Nov 25, 2024

  • Corporate

Organizational and Personnel Changes

TOKYO, November 25, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced the following organizational and personnel changes, effective January 1, 2025.

[Details of Organizational Changes]

1. Introduction of disease area-based branches in Marketing & Sales Div.

To strengthen and unify the head office functions of formulating disease area strategies with the Regional Management Offices functions of addressing challenges close to medical sites, we will reorganize the “branches” and “sections” of regional offices and transfer certain functions to the head office. This will establish a new sales structure to realize truly patient-centric healthcare.

Specifically, by dividing each branch into oncology and specialty areas, we will expand the facilities and areas covered by each branch, enabling them to plan and execute strategies with a broader perspective. By enhancing the organization's expertise, we aim to build stronger relationships of trust with healthcare professionals through in-depth discussions.

  • Introduce disease area-based branches for oncology and specialty within Regional Management Offices.
  • Consolidate branches and sections in accordance with personnel allocation aligned with disease area strategies.
  • Dissolve Area Strategy Execution Group, and its subordinate Oncology/Specialty Therapeutic Area Sects. and Solution Sect. within Regional Management Offices. Consequently, the functions of the specialized MRs in therapeutic area sections will be integrated into Oncology/Specialty Marketing Depts. The Medical Network Liaison/Team Healthcare Promotion functions of Solution Sect. will be integrated into Customer Solution Dept.
  • Newly establish Business Solutions Consolidated Management Sect. within Regional Management Offices, strengthening data analysis and digital transformation functions to execute strategies.

2. Reorganization of the Digital Transformation Unit

The organizational structure for developing and executing company-wide digital strategies, currently handled by Digital Strategy Dept., and the planning, building, and operating information systems, currently managed by IT Solution Dept., will be reorganized into strategies planning and execution functions. By consolidating the functions of both current departments, we aim to accelerate co-creation with various functions and establish a structure that can effectively and flexibly execute the shift to digital that creates even more value.

  • Reorganize the roles of the Digital Strategy Dept. and IT Solution Dept., and rename them to Digital Strategy Planning Dept. and Digital Solution Dept.

[Details of Personnel Changes]

Directors

NameNew ResponsibilitiesCurrent Responsibilities
Hitoshi Iikura

Director, Executive Vice President
Supervisory responsibility for Research, Translational Research, Clinical Development and Special Mission for CVF
Head of Translational Research Div.

Director, Executive Vice President
Supervisory responsibility for Research, Translational Research and Clinical Development
Head of Translational Research Div.

Executive Officers

NameNew ResponsibilitiesCurrent Responsibilities
Tetsuya Yamaguchi

Executive Vice President
Special Mission for CEO

Executive Vice President
Supervisory responsibility for PHC Solution, Partnering and Special Mission for CVF
Head of PHC Solution Unit
In charge of Partnering Dept.
Shinji Hidaka

Executive Vice President
Supervisory responsibility for Marketing & Sales, Drug Safety, Medical Affairs, PHC Solution and Special Mission for Overseas Marketing

Executive Vice President
Supervisory responsibility for Marketing & Sales, Drug Safety, and Medical Affairs
Tsukasa Kusano

Executive Vice President
Supervisory responsibility for Project & Lifecycle Management and Partnering
Head of Project & Lifecycle Management Unit
In charge of Partnering Dept.

Executive Vice President
Supervisory responsibility for Project & Lifecycle Management
Head of Project & Lifecycle Management Unit
Kaori Ouchi

Executive Vice President
Supervisory responsibility for Risk Management, Compliance, Quality & Regulatory Compliance, Pharmaceutical Technology and Manufacturing Technology
In charge of Risk & Compliance Dept.

Executive Vice President
Supervisory responsibility for Risk Management, Compliance, Quality & Regulatory Compliance, Pharmaceutical Technology and Manufacturing Technology
Masayoshi Higuchi

Vice President
Special Mission for CEO

Vice President
Head of Quality & Regulatory Compliance Unit
In charge of Risk & Compliance Dept.

Please see the PDF file about other personnel changes.

[PDF 368KB]

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp

Back